Cellectis Wins 2016 Most Innovative European Biotech SME Award for Healthcare
September 27 2016 - 5:00PM
Business Wire
Cellectis (Alternext: ALCLS – Nasdaq: CLLS), a biopharmaceutical
company focused on developing immunotherapies based on gene edited
CAR T-cells (UCART), today announced that the Company has won
EuropaBio’s 2016 Most Innovative European Biotech SME Award for the
healthcare category. The Awards program represents a unique annual
initiative (now in its seventh year) that recognizes innovative
biotech small- and medium-sized enterprises (SMEs) in Europe and
the crucial role that they play in answering some of society’s
greatest challenges through biotechnology.
Cellectis’ selection was based on the Company’s contribution to
and impact on the global healthcare and life sciences industries
via its development and therapeutic application of allogeneic CAR
T-cell immunotherapies that target cancer. In this process, T-cells
from healthy donors are genetically edited with Cellectis’ TALEN®
technology to seek and destroy cancer cells.
“It is an honor for Cellectis to receive this award for our
pioneering gene editing technology and immunotherapies, which will
bring cutting-edge cancer treatment globally to patients who have
high unmet medical needs,” said Dr. André Choulika, Chairman and
Chief Executive Officer, Cellectis. “As we work hard to bring our
product candidates to patients, programs like the EuropaBio SME
Awards create an environment of strong support and a platform for
discussing continuing innovation for bioscience companies across
the board.”
“Raising the profile for innovative biotech companies in Europe,
both collectively and individually, offers the opportunity to
demonstrate the enormous potential of our entrepreneurs in this
sector,” added Tom Saylor, Chairman of the EuropaBio SME Platform.
“Finalists enjoy the chance to showcase their capabilities to
potential partners, investors and collaborators, and past finalists
have shown that this award can provide a platform for access to
resources and exposure that can contribute to ongoing success in
the future.”
About Cellectis
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The
company’s mission is to develop a new generation of cancer
therapies based on engineered T-cells. Cellectis capitalizes on its
16 years of expertise in genome engineering - based on its flagship
TALEN® products and meganucleases and pioneering electroporation
PulseAgile technology - to create a new generation of
immunotherapies. CAR technologies are designed to target surface
antigens expressed on cells. Using its life-science-focused,
pioneering genome-engineering technologies, Cellectis’ goal is to
create innovative products in multiple fields and with various
target markets. Cellectis is listed on the Nasdaq market (ticker:
CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out
more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it.TALEN® is a registered
trademark owned by the Cellectis Group.
About EuropaBio’s European Biotech SME Awards 2016
EuropaBio, the European Association for Bioindustries, invited
SMEs across Europe to apply for the 7th edition of the Most
Innovative European Biotech SME Award. Depending on their field of
activity, SMEs could apply in 3 categories: healthcare,
agricultural or industrial biotech. Three companies were
shortlisted in each category by a jury or biotech experts, with the
winners celebrated during a landmark event for SMEs held in the
course of European Biotech Week in late September.
The members of EuropaBio are involved in research, development,
testing, manufacturing and commercialization of biotech products
and processes in human and animal healthcare, diagnostics,
bioinformatics, chemicals, crop protection, agriculture, food and
environmental products and services. EuropaBio also counts a number
of National Biotech Associations in its membership who in turn
represent more than 1800 biotech SMEs. EuropaBio’s SME Platform
focuses its activities on highlighting challenges and financial
constraints that biotech SMEs face, and developing policy
recommendations to optimise EU and member state funding instruments
for biotech SMEs. The SME Platform brings together CEOs of SMEs,
National Biotech Associations, Venture Capitalists and private
banks, European financial institutions, representatives from the
EC, and other interested stakeholders.
Disclaimer
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an
offer to buy or subscribe, for shares in Cellectis in any country.
This press release contains forward-looking statements that relate
to the Company’s objectives based on the current expectations and
assumptions of the Company’s management only and involve risk and
uncertainties that could cause the Company to fail to achieve the
objectives expressed by the forward-looking statements above.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160927006684/en/
Media:Jennifer Moore, 917-580-1088VP of
Communicationsmedia@cellectis.comorCaitlin Kasunich,
212-896-1241KCSA Strategic
Communicationsckasunich@kcsa.comorIR:Simon Harnest,
646-385-9008VP of Corporate Strategy and
Financesimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2023 to Apr 2024